ASTH Quote, Financials, Valuation and Earnings

Biote has a net margin of 1.08% compared to Astrana Health's net margin of 28%. Astrana Health's return on equity of 7.09% beat Biote's return on equity of --.

Astrana Health has a consensus price target of $47.4444, signalling upside risk potential of 92.16%. On the other hand Biote has an analysts' consensus of $6.40 which suggests that it could grow by 53.43%. Given that Astrana Health has higher upside potential than Biote, analysts believe Astrana Health is more attractive than Biote.

Astrana Health has a beta of 0.842, which suggesting that the stock is 15.811% less volatile than S&P 500. In comparison Biote has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Astrana Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biote offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astrana Health pays 9.35% of its earnings as a dividend. Biote pays out 150.27% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Biote's is not.

Astrana Health quarterly revenues are $620.4M, which are larger than Biote quarterly revenues of $49M. Astrana Health's net income of $6.7M is lower than Biote's net income of $13.7M. Notably, Astrana Health's price-to-earnings ratio is 34.32x while Biote's PE ratio is 6.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health is 0.53x versus 0.73x for Biote. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of 1.08% compared to Astrana Health's net margin of 4.49%. Astrana Health's return on equity of 7.09% beat Cryo-Cell International's return on equity of --.

Astrana Health has a consensus price target of $47.4444, signalling upside risk potential of 92.16%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 75.26%. Given that Astrana Health has higher upside potential than Cryo-Cell International, analysts believe Astrana Health is more attractive than Cryo-Cell International.

Astrana Health has a beta of 0.842, which suggesting that the stock is 15.811% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.659, suggesting its less volatile than the S&P 500 by 34.131%.

Astrana Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 13.4% to investors and pays a quarterly dividend of $0.15 per share. Astrana Health pays 9.35% of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Cryo-Cell International's is not.

Astrana Health quarterly revenues are $620.4M, which are larger than Cryo-Cell International quarterly revenues of $7.9M. Astrana Health's net income of $6.7M is higher than Cryo-Cell International's net income of $355.8K. Notably, Astrana Health's price-to-earnings ratio is 34.32x while Cryo-Cell International's PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health is 0.53x versus 1.25x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

Omnicell has a net margin of 1.08% compared to Astrana Health's net margin of -2.6%. Astrana Health's return on equity of 7.09% beat Omnicell's return on equity of 1.73%.

Astrana Health has a consensus price target of $47.4444, signalling upside risk potential of 92.16%. On the other hand Omnicell has an analysts' consensus of $43.33 which suggests that it could grow by 55.99%. Given that Astrana Health has higher upside potential than Omnicell, analysts believe Astrana Health is more attractive than Omnicell.

Astrana Health has a beta of 0.842, which suggesting that the stock is 15.811% less volatile than S&P 500. In comparison Omnicell has a beta of 0.761, suggesting its less volatile than the S&P 500 by 23.879%.

Astrana Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astrana Health pays 9.35% of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Astrana Health quarterly revenues are $620.4M, which are larger than Omnicell quarterly revenues of $269.7M. Astrana Health's net income of $6.7M is higher than Omnicell's net income of -$7M. Notably, Astrana Health's price-to-earnings ratio is 34.32x while Omnicell's PE ratio is 60.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health is 0.53x versus 1.14x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of 1.08% compared to Astrana Health's net margin of -5.49%. Astrana Health's return on equity of 7.09% beat P3 Health Partners's return on equity of -53.56%.

Astrana Health has a consensus price target of $47.4444, signalling upside risk potential of 92.16%. On the other hand P3 Health Partners has an analysts' consensus of $8.00 which suggests that it could grow by 23.08%. Given that Astrana Health has higher upside potential than P3 Health Partners, analysts believe Astrana Health is more attractive than P3 Health Partners.

Astrana Health has a beta of 0.842, which suggesting that the stock is 15.811% less volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Astrana Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astrana Health pays 9.35% of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Astrana Health quarterly revenues are $620.4M, which are larger than P3 Health Partners quarterly revenues of $373.2M. Astrana Health's net income of $6.7M is higher than P3 Health Partners's net income of -$20.5M. Notably, Astrana Health's price-to-earnings ratio is 34.32x while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health is 0.53x versus 0.01x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.